natgillin/translations-raw huggingface dataset:
The active substance in Doxorubicin SUN and Caelyx, doxorubicin, is a cytotoxic medicine that belongs to the group ‘anthracyclines'. 
Zdravilna učinkovina v zdravilu Doxorubicin SUN in Caelyx, doksorubicin, je citotoksično zdravilo iz skupine „antraciklinov“.
Doxorubicin SUN is concentrate to be made up into a solution for infusion (drip into a vein). 
Zdravilo Doxorubicin SUN je koncentrat, ki se pripravi v raztopino za infundiranje (kapalna infuzija v veno).
What was Doxorubicin SUN expected to be used for? 
Za kaj naj bi se zdravilo Doxorubicin SUN uporabljalo?
How was Doxorubicin SUN expected to work? 
Kako naj bi zdravilo Doxorubicin SUN delovalo?
18 August 2011 
dnevu“.
Information on the reference medicine can also be found on the Agency's website. 
Informacije o referenčnem zdravilu so prav tako na voljo na spletni strani agencije.
Further information on Pazenir can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/pazenir. 
Nadaljnje informacije o zdravilu Pazenir so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/pazenir.
The medicine is given once a day on days 1, 8 and 15 of each cycle. 
Daje se enkrat na dan na 1., 8. in 15. dan vsakega cikla.
What measures are being taken to ensure the safe and effective use of Pazenir? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pazenir?
The recommended dose depends on the patient's height and weight. 
Priporočeni odmerek je odvisen od bolnikove telesne mase in višine.
‘Metastatic' means that the cancer has spread to other parts of the body; 
„Metastatski“ pomeni, da se je rak razširil na druge dele telesa;
Pazenir received a marketing authorisation valid throughout the EU on 6 May 2019. 
Za zdravilo Pazenir je bilo 6. maja 2019 izdano dovoljenje za promet, veljavno po vsej EU.
It should not be interchanged with other medicines containing paclitaxel. 
Ne sme se nadomeščati z drugimi zdravili, ki vsebujejo paklitaksel.
As for every medicine, the company provided studies on the quality of Pazenir. 
Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Pazenir.
Paclitaxel has been available as a cancer medicine since 1993. 
Paklitaksel je kot zdravilo za zdravljenje raka na voljo od leta 1993.
For more information on generic medicines, see the question-and-answer document here. 
Za več informacij o generičnih zdravilih si oglejte dokument z vprašanji in odgovori, ki je na voljo tukaj.
What are the benefits and risks of Pazenir? 
Kakšne so koristi in tveganja, povezani z zdravilom Pazenir?
Why is Pazenir authorised in the EU? 
Zakaj je bilo zdravilo Pazenir odobreno v EU?
An overview of Pazenir and why it is authorised in the EU 
Pregled zdravila Pazenir in zakaj je odobreno v EU
By keeping this structure intact, the cells cannot divide and they eventually die. 
Z ohranjanjem celičnega skeleta se celice ne morejo deliti in sčasoma odmrejo.
Paclitaxel blocks a stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide. 
Paklitaksel zavira fazo delitve celic, med katero se notranji „skelet“ celice razgradi, kar ji omogoča delitev.
What is Pazenir and what is it used for? 
Kaj je zdravilo Pazenir in za kaj se uporablja?
The European Medicines Agency concluded that, in accordance with EU requirements, Pazenir has been shown to be comparable to Abraxane. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Pazenir primerljivo z zdravilom Abraxane.
Pazenir is used to treat the following cancers in adults: 
Zdravilo Pazenir se uporablja za zdravljenje naslednjih vrst raka pri odraslih:
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Abraxane, and do not need to be repeated for Pazenir. 
Študije o koristih in tveganjih učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Abraxane, zato jih ni treba ponoviti za zdravilo Pazenir.
As for all medicines, data on the use of Pazenir are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Pazenir stalno spremljajo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pazenir have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pazenir upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
For more information about using Pazenir, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Pazenir glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Pazenir 
Druge informacije o zdravilu Pazenir
Pazenir also affects non-cancer cells such as blood and nerve cells, which can cause side effects. 
Zdravilo Pazenir učinkuje tudi na nerakave celice, kot so krvne ali živčne celice, kar lahko povzroči neželene učinke.
Immediately after giving Pazenir, gemcitabine should be given. 
Takoj po dajanju zdravila Pazenir mora bolnik prejeti tudi gemcitabin.
Side effects reported with Pazenir are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Pazenir, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Because Pazenir is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Pazenir generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
This makes it easy to prepare a suspension of paclitaxel, which can be infused into a vein. 
To olajša pripravo raztopine s paksitakselom, ki se lahko infundira v veno.
In non-small cell lung cancer, treatment is carried out in 3-week cycles with Pazenir given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Pazenir. 
Pri nedrobnoceličnem pljučnem raku se zdravljenje izvaja v tritedenskih ciklih, in sicer se zdravilo Pazenir daje na 1., 8. in 15. dan vsakega cikla, karboplatin pa na 1. dan cikla takoj po infundiranju zdravila Pazenir.
This means that Pazenir contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Abraxane. 
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Abraxane.
• metastatic breast cancer, when the first treatment has stopped working and standard treatment including an anthracycline (another type of cancer medicine) is not suitable. 
• metastatskega raka dojk, kadar je prvotno zdravljenje postalo neučinkovito, standardno zdravljenje, ki vključuje antracikline (drugo vrsto zdravil za zdravljenje raka), pa ni primerno.
This is because Pazenir is given by infusion into a vein and the nanoparticles it contains rapidly separate into its constituent parts in the same way as Abraxane's. 
Razlog za to je, da se zdravilo Pazenir daje z infundiranjem v veno in nanodelci, ki jih vsebuje, hitro razpadejo na sestavne dele na enak način kot pri zdravilu Abraxane.
There was no need for ‘bioequivalence' studies to investigate whether Pazenir is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. 
Izvedba študije „bioekvivalence“, s katero bi raziskali, ali se zdravilo Pazenir absorbira podobno kot referenčno zdravilo in tako doseže enako raven učinkovine v krvi, ni bila potrebna.
Pazenir is given as an infusion into a vein over a period of 30 minutes. 
Zdravilo Pazenir se daje z infundiranjem v veno, ki traja 30 minut.
Pazenir should only be given under the supervision of a cancer doctor in clinics that are specialised in giving ‘cytotoxic' (cell-killing) medicines. 
Zdravilo Pazenir se lahko daje samo pod nadzorom zdravnika specialista za rakava obolenja v bolnišnicah, ki so specializirana za dajanje citotoksičnih zdravil (zdravil, ki uničujejo celice).
In Pazenir, as in its reference medicine Abraxane, paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles'. 
V zdravilu Pazenir (enako kot v njegovem referenčnemu zdravilu Abraxane) je paklitaksel vezan na človeško beljakovino albumin v drobnih delcih, imenovanih nanodelci.
• metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine; 
• metastatskega adenokarcinoma trebušne slinavke, pri katerem se uporablja kot zdravilo prve izbire v kombinaciji z drugim zdravilom za zdravljenje raka, tj. gemcitabinom;
The active substance in Pazenir, paclitaxel, belongs to the group of cancer medicines known as the ‘taxanes'. 
Učinkovina v zdravilu Pazenir, paklitaksel, spada v skupino zdravil za zdravljenje raka, imenovanih taksani.
Pazenir contains the active substance paclitaxel attached to a human protein called albumin and is a ‘generic medicine'. 
Zdravilo Pazenir vsebuje učinkovino paklitaksel, vezano na človeško beljakovino, imenovano albumin, in je generično zdravilo.
• non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy. 
• nedrobnoceličnega pljučnega raka, pri katerem se uporablja kot zdravilo prve izbire v kombinaciji z zdravilom za zdravljenje raka, imenovanim karboplatin, pri bolnikih, pri katerih kirurški poseg ali obsevanje nista primerna.
In metastatic breast cancer, Pazenir is given on its own every three weeks. 
Pri metastatskem raku dojk se zdravilo Pazenir vsake tri tedne daje kot samostojno zdravilo.
In metastatic adenocarcinoma of the pancreas, Pazenir is given in 4-week treatment cycles. 
Pri metastatskem adenokarcinomu trebušne slinavke se zdravilo Abraxane daje v štiritedenskih ciklih zdravljenja.
How has Pazenir been studied? 
Kako je bilo zdravilo Pazenir raziskano?
Therefore, the Agency's view was that, as for Abraxane, the benefits of Pazenir outweigh the identified risks and it can be authorised for use in the EU. 
Menila je, da koristi zdravila Pazenir enako kot pri zdravilu Abraxane odtehtajo znana tveganja in da se zdravilo lahko odobri za uporabo v EU.
How is Pazenir used? 
Kako se zdravilo Pazenir uporablja?
How does Pazenir work? 
Kako zdravilo Pazenir deluje?
Rash and Severe Cutaneous Adverse Reactions safety data from Phases 2 and 3 Incidence of rash and severe cutaneous reactions Grading and management of rash and severe cutaneous reactions, particularly with respect to criteria for the continuation or discontinuation of telaprevir and the other 
Navodilo za uporabo za zdravnike mora vsebovati naslednje ključne elemente: podatke o varnosti iz študij fazeIIinIII o izpuščaju in hudih kožnih reakcijah pojavnost izpuščaja in hudih kožnih reakcij merila za oceno in zdravljenje izpuščaja in hudih kožnih reakcij, še posebno kriterije za nadaljevanje ali prekinitev zdravljenja s telaprevirjem in drugimizdravili slike izpuščajev različnih stopenj
The Member States shall ensure that the MAH provides to all physicians who are expected to prescribe or use INCIVO a healthcare professional educational pack containing the following: 
Imetnik dovoljenja za promet z zdravilom bo zagotovil, da bodo zdravniki, ki bodo predpisovali ali uporabljali zdravilo INCIVO prejeli izobraževalno gradivo, ki bo vsebovalo: Povzetek glavnih značilnosti zdravila
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: 
DODATEK POGOJI IN OMEJITVE GLEDE VARNE IN UČINKOVITE UPORABE ZDRAVILA
The Member States shall agree to the final healthcare educational pack with the Marketing Authorization Holder (MAH) prior to launch of the product in their territory. 
Imetnik dovoljenja za promet z zdravilom se bo za obliko in vsebino izobraževalnih gradiv za zdravstvene delavce pred dajanjem zdravila na trg dogovoril s pristojnim nacionalnim organom države članice.
The Summary of Product Characteristics 
Navodilo za uporabo za bolnike
250 µg Solution for injection 
250 µg Raztopina za injiciranje
5 capsules 
5 kapsul
Intravenous use vial (glass) 5 ml 
Intravensko Viala (steklo)
Packaging Content (concentration) Package size 
Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina velikost pakiranja
If you are in a compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you. 
Če ste vključeni v program sočutne uporabe in potrebujete več informacij o zdravljenju, se obrnite na zdravnika, ki vam je predpisal zdravljenje.
The conditions are caused by a lack of enzymes needed to remove them. 
Bolezni sta posledica pomanjkanja encimov, ki so potrebni za odstranjevanje navedenih snovi.
In its letter notifying the Agency of the withdrawal of the application, the company stated that it needed more time to prepare adequate answers to questions raised by the CHMP. 
Družba je v dopisu, s katerim je agencijo obvestila o umiku vloge, navedla, da potrebuje več časa za pripravo ustreznih odgovorov na vprašanja, ki jih je zastavil odbor CHMP.
Prohippur was not studied directly in patients with these conditions. 
Zdravila Prohippur niso proučevali neposredno pri bolnikih s temi boleznimi.
What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes? 
Kakšne so posledice umika vloge za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila?
It was to be available as granules. 
Na voljo naj bi bilo v obliki zrnc.
Prohippur is a medicine containing the active substance sodium benzoate. 
Prohippur je zdravilo, ki vsebuje učinkovino natrijev benzoat.
Finally, the CHMP had questions about the high levels of a substance in Prohippur (butylated methacrylate copolymer), the method of administration and quality control of the medicine in general. 
Na koncu je imel odbor CHMP tudi vprašanja o visokih ravneh snovi v zdravilu Prohippur (kopolimera butiliranega metakrilata), načinu dajanja zdravila in nadzoru kakovosti zdravila na splošno.
The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated lists of questions. 
Vlogo so umaknili po tem, ko je odbor CHMP že ocenil dokumentacijo, ki jo je predložila družba, in oblikoval seznam vprašanj.
The company informed the CHMP that there are no ongoing clinical trials with Prohippur and that a compassionate use programme approved in France will continue as planned. 
Družba je odbor CHMP obvestila, da trenutno ne potekajo klinična preskušanja zdravila Prohippur in da se bo program sočutne uporabe, odobren v Franciji, nadaljeval po načrtu.
Prohippur was expected to be used to treat the following inherited disorders: 
Zdravilo Prohippur naj bi se uporabljalo za zdravljenje naslednjih dednih bolezni:
Prohippur was designated an ‘orphan medicine' (a medicine to be used in rare diseases) for non-ketotic hyperglycinaemia on 11 September 2002 and for urea cycle disorders on 14 July 2016, 29 August 2016 and 18 November 2016. 
Zdravilo Prohippur je bilo 11. septembra 2002 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni) za zdravljenje neketotične hiperglicinemije ter 14. julija 2016, 29. avgusta 2016 in 18. novembra 2016 za zdravljenje motenj ciklusa sečnine.
Both glycine and ammonia are harmful in high amounts and can cause severe brain damage. 
Glicin in amoniak sta v večjih količinah škodljiva in lahko povzročata hude možganske poškodbe.
The company had not responded to the last round of questions at the time of the withdrawal. 
Družba ob umiku vloge še ni odgovorila na zadnji sklop vprašanj.
Prohippur also helps remove excess nitrogen from the body, thereby lowering levels of ammonia. 
Zdravilo Prohippur prav tako pomaga odstraniti odvečni dušik iz telesa in tako zniža raven amoniaka.
The CHMP noted that the published studies submitted by the company did not provide enough evidence of the effectiveness and safety of sodium benzoate in the various disorders. 
Ugotovil je, da objavljene študije, ki jih je predložila družba, ne zagotavljajo dovolj dokazov o učinkovitosti in varnosti natrijevega benzoata pri različnih boleznih.
On 3 April 2018, Lucane Pharma officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wished to withdraw its application for a marketing authorisation for Prohippur, for the treatment of non-ketotic hyperglycinaemia and urea cycle disorders. 
Družba Lucane Pharma je 3. aprila 2018 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Prohippur, namenjenim zdravljenju neketotične hiperglicinemije in motenj ciklusa sečnine.
Furthermore, as Prohippur was not used in clinical trials, the company should have provided data to show that Prohippur granules worked in the same way as the sodium benzoate used in the published studies. 
Ker se zdravilo Prohippur ni uporabljalo v kliničnih preskušanjih, bi morala družba predložiti podatke, ki kažejo, da zrnca zdravila Prohippur delujejo enako kot natrijev benzoat, ki so ga uporabljali v objavljenih študijah.
The active substance in Prohippur, sodium benzoate, helps reduce harmful levels of glycine by attaching to glycine and forming a substance that is more easily removed by the kidneys. 
Učinkovina zdravila Prohippur, natrijev benzoat, pomaga znižati škodljive ravni glicina, tako da se pritrdi na glicin in tvori snov, ki jo ledvice lažje odstranijo.
What was Prohippur expected to be used for? 
Za kaj naj bi se zdravilo Prohippur uporabljalo?
The company presented data from published studies on the use of sodium benzoate in patients with non-ketotic hyperglycinaemia and urea cycle disorders. 
Družba je predložila podatke objavljenih študij o uporabi natrijevega benzoata pri bolnikih z neketotično hiperglicinemijo in motnjami ciklusa sečnine.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Prohippur did not outweigh its risks. 
Zato je ob umiku vloge menil, da koristi zdravila Prohippur ne odtehtajo z njim povezanih tveganj.
• non-ketotic hyperglycinaemia, where abnormally high levels of the amino acid glycine occur in the blood. 
• neketotične hiperglicinemije, pri kateri se v krvi pojavljajo nenormalno visoke ravni aminokisline glicina;
• urea cycle disorders, a group of conditions where abnormally high levels of nitrogen occur in the body in the form of ammonia. 
• motenj ciklusa sečnine, tj. skupine stanj, pri katerih se v telesu pojavljajo nenormalno visoke ravni dušika v obliki amoniaka.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom27 April 2018 EMA/258015/2018 EMEA/H/C/004150 
EMA/258015/2018 EMEA/H/C/004150
At the time of the withdrawal, the CHMP had some concerns. 
Odbor CHMP je ob umiku vloge izrazil določene zadržke.
What is Prohippur? 
Kaj je zdravilo Prohippur?
How does Prohippur work? 
Kako zdravilo Prohippur deluje?
5 years. 
5 leta
Date of first authorisation: 20 November 2002 Date of latest renewal: 20 November 2012 
Datum prve odobritve: 20. november 2002 Datum zadnjega podaljšanja: 20. november 2012
A relevance of these findings to humans cannot be excluded. 
Pomembnost teh ugotovitev za človeka ni mogoče izključiti.
You should swallow the whole capsule with a glass of water. 
Kapsulo morate pogoltniti cele s kozarcem vode.
The other ingredients are: 
Druge sestavine zdravila so:
Recommended dose 200 mg three times a day 200 mg twice a day 100 mg three times a day 100 mg twice a day 100 mg once a day 
200 mg trikrat dnevno 200 mg dvakrat dnevno 100 mg trikrat dnevno 100 mg dvakrat dnevno 100 mg enkrat dnevno
If you have a problem with your kidneys you may receive a lower starting dose. 
Če imate težave s svojimi ledvicami, lahko dobite manjši začetni odmerek.
- if you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 6) 
- če ste alergični na miglustat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Maximum plasma concentrations are reached about 2 hours after dose. 
Najvišje koncentracije v plazmi dosega približno 2 uri po odmerku.
Weight loss has been reported in 55% of patients. 
O izgubi telesne mase so poročali pri približno 55 % bolnikov.
Do not take this medicine after the expiry date which is stated on the carton after ‘EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake »EXP«.
• Risk Management Plan (RMP) 
ZDRAVILA • Načrt za obvladovanje tveganj (RMP)
A No Observed Effect Level (NOEL) was not established and the effect was not dose dependent. 
Ravni brez opaženega učinka (NOEL - ˝No Observed Effect Level˝) niso ugotovili, učinek ni bil odvisen od odmerka.
This leaflet was last revised in: 
Navodilo je bilo nazadnje revidirano dne:
The tremor often disappears without needing to stop the treatment. 
Tremor pogosto izgine brez potrebe prekinitve zdravljenja z zdravilom Zavesca.
What Zavesca is and what it is used for 
Kaj je zdravilo Zavesca in za kaj ga uporabljamo
Capsule, hard 84 capsules 
kapsula, trda 84 kapsul
Patients with chronic diarrhoea or other persistent gastrointestinal events that do not respond to these interventions should be investigated according to clinical practice. 
Bolnike s kronično diarejo ali drugimi trdovratnimi prebavnimi težavami, ki se na te ukrepe ne odzovejo, je treba preiskati skladno s klinično prakso.
Zavesca can be taken with or without food. 
Zdravilo Zavesca se lahko jemlje s hrano ali brez nje.
Most serious side effects: 
Najresnejši neželeni učinki:
The tests will help the doctor decide whether these effects are due to your disease or other existing conditions, or due to side effects of Zavesca (see section 4 for further details). 
Te preiskave bodo zdravniku v pomoč pri presoji, ali so ti učinki posledica vaše bolezni ali drugega obstoječega stanja ali posledica neželenih učinkov zdravila Zavesca (za dodatne informacije glejte poglavje 4).
What Zavesca is and what it is used for What you need to know before you take Zavesca How to take Zavesca 
Kaj je zdravilo Zavesca in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Zavesca Kako jemati zdravilo Zavesca
Concomitant administration of food decreases the rate of absorption (Cmax was decreased by 36% and tmax delayed 2 hours), but has no statistically significant effect on the extent of absorption of miglustat (AUC decreased by 14%). 
Sočasno jemanje s hrano zniža raven absorpcije (Cmax se je znižal za 36 % in tmax podaljšal za 2 uri), vendar nima statistično značilnega učinka na absorpcijo miglustata (AUC se je znižala za 14 %).
If you are pregnant, breast feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Tell your doctor if you are taking medicines containing imiglucerase, which are sometimes used at the same time as Zavesca. 
Obvestite zdravnika, če jemljete zdravila, ki vsebujejo imiglucerazo, ki se včasih jemljejo skupaj z zdravilom Zavesca.
They may lower the amount of Zavesca in your body. 
Ta zdravila lahko znižajo količino zdravila Zavesca v vašem telesu.
It is not known if miglustat is secreted in breast milk. 
Ni znano, ali se miglustat izloča v materino mleko.
Among the 41 patients enrolled in the trial 14 patients were treated with Zavesca for more than 3 years. 
Med 41 bolniki, vključenimi v preskušanje, je bilo 14 bolnikov zdravljenih z zdravilom Zavesca več kot 3 leta.
Do not give this medicine to children and adolescents (below 18 years old) with type 1 Gaucher disease because it is not known if it works in this disease. 
Tega zdravila ne dajajte otrokom in mladostnikom (starim manj kot 18 let) z Gaucherjevo boleznijo tipa 1, saj njegov učinek na to bolezen ni znan.